Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Sitagliptin/metformin

Rosiglitazone (Avandia) Rosiglitazone/Metformin (Avandamet) Sitagliptin (Januvia) Sitagliptin/Metformin (Janumet)... [Pg.45]

Sitagliptin is a dipeptidylpeptidase-4 inhibitor that increases insulin secretion and lowers glucagon secretion. Sitagliptin is available for oral administration. It is indicated in patients with type 2 diabetes mellitus in combination with either metformin (biguanide) or a sulphonylurea or a thiazolidinedione. [Pg.154]

Sitagliptin is a selective dipeptidylpeptidase 4 (DPP-4) inhibitor which increases the active form of GLP-1 (glucagon-like-peptide-1) and GIP (glucose-dependent insulinotropic peptide). This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Adverse effects were as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for nausea and common cold-like symptoms. [Pg.397]

Charbonel B, Karasik A, Ji Liu, Mei Wu, Meininger G, for the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 2638-43. [Pg.777]

In a placebo-controlled, multiple-dose, crossover study in 13 patients with type 2 diabetes, sitagliptin 50 mg bd and metformin 1000 mg bd did not alter the pharmacokinetics of each other (7). [Pg.384]

Herman GA, Bergman A, Yi B, Kipnes M The Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006 22(10) 1939 t7. [Pg.384]

Karasik A, Charbonnell B, Liu J, Wu M, Meehan A, Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes (abstract 501-P). Diabetes 2006 55(Suppl. 1) A 119-120. [Pg.142]

Metabolism Two women developed hypoglycemia when taking sitagliptin 100 mg/ day-I-metformin after 75 and 113 days in... [Pg.689]

Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010 26 540-9. [Pg.700]

Seek T, Nauck M, Sunga S, Davies MJ, Stein PP, Kaufinan KD, Amatruda JM Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin a 2-year study. Int J Clin Pract 2010 64(5) 562-76. [Pg.700]

Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglita-zone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2) a randomised trial. Lancet 2010 376 431-9. [Pg.701]

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M 1860-LIRA-DPP-4 Study Group. Liraglu-tide versus sitagliptin for patients with type 2 diabetes who did not have adequate gly-caemic control with metformin a 26 week randomised parallel-group open-label trial. Lancet 2010 375 1447-56. [Pg.701]

Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with Uraglutide in patients with type 2 diabetes meUitus inadequately controlled on metformin a randomised clinical trial. Diabetologia 2013 56(7) 1503-11. [Pg.656]

LavaUe-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy a randomised trial. Diabetologia 2013 56(12) 2582-92. [Pg.656]

Sitagliptin 5 (Januvia, Figure 4.2) is an oral antidiabetic drug of the DPP-4 inhibitor class developed and is marketed by Merck Co. Sitagliptin is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for the treatment of type-2 diabetes. [Pg.72]

See other pages where Sitagliptin/metformin is mentioned: [Pg.657]    [Pg.107]    [Pg.542]    [Pg.284]    [Pg.758]    [Pg.946]    [Pg.102]    [Pg.284]    [Pg.129]    [Pg.130]    [Pg.137]    [Pg.496]    [Pg.33]    [Pg.284]    [Pg.119]    [Pg.119]    [Pg.121]    [Pg.122]    [Pg.124]    [Pg.124]    [Pg.125]    [Pg.128]    [Pg.33]    [Pg.688]    [Pg.689]    [Pg.650]    [Pg.639]    [Pg.640]    [Pg.373]   
See also in sourсe #XX -- [ Pg.284 ]



SEARCH



Metformin

© 2024 chempedia.info